{"nctId":"NCT00681590","briefTitle":"Safety of Vitamin D Supplementation in Older Persons","startDateStruct":{"date":"2008-04"},"conditions":["Vitamin D Deficiency"],"count":105,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: cholecalciferol (vitamin D)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: cholecalciferol (vitamin D)"]}],"interventions":[{"name":"cholecalciferol (vitamin D)","otherNames":[]},{"name":"cholecalciferol (vitamin D)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ambulatory\n\nExclusion Criteria:\n\n* hypercalcemia\n* hypercalciuria \\> 4 mg/kg body weight/day\n* primary, secondary, or tertiary hyperparathyroidism\n* renal insufficiency (serum creatinine \\> 2 mg/dL )\n* history of nephrolithiasis\n* treatment with vitamin D (ergocalciferol, cholecalciferol, calcitriol)\n* treatment with anticonvulsants\n* Paget's disease\n* severe cardiac, pulmonary, hepatic, renal, or neurological disease\n* life expectancy \\< 1 year\n* participation in another trial","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","maximumAge":"95 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Develop Hypercalcemia","description":"calcium serum levels measured at baseline and at the end of the intervention (6-months)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum 25-hydroxyvitamin D Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1"},{"groupId":"OG001","value":"6.5","spread":"6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["hypercalcemia"]}}}